Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH.

J Rheumatol. 2008 Sep;35(9):1737-44. Epub 2008 Jul 15.

2.

Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.

Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF.

J Manag Care Spec Pharm. 2014 Nov;20(11):1110-20.

3.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
4.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
5.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

6.

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.

7.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
9.

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.

Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH.

Ann Rheum Dis. 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435. Epub 2014 Dec 3.

PMID:
25471471
10.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
11.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
12.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.

13.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

14.
15.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

16.

Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.

Cho SK, Sung YK, Choi CB, Bae SC.

Rheumatol Int. 2012 Dec;32(12):3851-6. doi: 10.1007/s00296-011-2312-1. Epub 2011 Dec 23.

PMID:
22193228
17.

Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.

Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G.

Joint Bone Spine. 2015 May;82(3):187-91. doi: 10.1016/j.jbspin.2014.12.006. Epub 2015 Jan 22.

PMID:
25619156
18.

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.

Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):67-76. doi: 10.1002/art.39416.

19.

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

PMID:
17611987
20.

The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.

Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL.

J Rheumatol. 2009 Oct;36(10):2171-7. doi: 10.3899/jrheum.090054. Epub 2009 Sep 1.

PMID:
19723902

Supplemental Content

Support Center